Grupo Zendal | Prensa

El Grupo Zendal

Biofarmacéuticos

NOTICIA

19 · 05 · 2023

Spanish biotech Zendal and IAVI announce expanded agreement to partner on development of TB vaccine candidate MTBVAC

Contacto de prensa

19 · 05 · 2023Spanish biotech Zendal and IAVI announce expanded agreement to partner on development of TB vaccine candidate MTBVAC

05 · 05 · 2023FEUGA holds the Governing Board in Zendal

18 · 04 · 2023Zendal holds an integration day with the recently acquired Laboratorios Maymó

01 · 03 · 2023The Zendal Group acquires 100% of Maymo and strengthens its expansion plan

13 · 02 · 2023Zendal Group promotes the incorporation of female talent

19 · 01 · 2023The CSIC and Zendal develop a new vaccine against canine leishmaniasis

29 · 09 · 2022The Zendal Group strengthens the management organization chart with new incorporations and an eye focused on the growth plan

26 · 08 · 2022Zendal group increases its support for new research projects and doubles the amount of its annual prizes

17 · 03 · 2022BIOFABRI and BHARAT BIOTECH partner to develop, manufacture and distribute a novel TB vaccine, MTBVAC.

20 · 07 · 2021Spanish pharmaceutical company Zendal and IAVI partner to advance the tuberculosis vaccine candidate MTBVAC into efficacy trials

20 · 07 · 2021MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG Vaccine

23 · 03 · 2021MTBVAC in new-borns Phase 2a trial completed its enrolment